Table 2 Distribution of primary and secondary study endpoints as well as preservation solutions to the different eras, 2554 patients from the Hannover liver transplant program
Era | |||||
|---|---|---|---|---|---|
I | II | III | IV | p-value | |
n (%) | 346 (13.5%) | 773 (30.3%) | 811 (31.8%) | 624 (24.4%) | n.a. |
HTK | 32 (9.2%) | 470 (60.8%) | 439 (54.1%) | 522 (83.7%) | <0.0011 |
UW | 314 (90.8%) | 303 (39.2%) | 372 (45.9%) | 102 (16.3%) | <0.0011 |
3 months mortality | 82 (23.7%) | 142 (18.4%) | 112 (13.8%) | 98 (15.7%) | <0.0011 |
graft loss | 224 (64.7%) | 374 (48.4%) | 281 (34.6%) | 171 (27.4%) | <0.0011 |
3 month graft survival | 238 (68.8%) | 582 (75.3%) | 645 (79.5%) | 482 (77.4%) | 0.0011 |
HAT | 14 (4.0%) | 19 (2.5%) | 30 (3.8%) | 37 (6.0%) | 0.0101 |
Portal vein thrombosis | 6 (1.9%) | 7 (0.9%) | 24 (3.1%) | 27 (4.4%) | 0.0011 |
Caval vein thrombosis | 1 (0.3%) | 4 (0.5%) | 10 (1.3%) | 31 (5.0%) | <0.0011 |
Post-operative hemorrhage | 73 (22.7%) | 197 (25.9%) | 162 (20.8%) | 169 (27.3%) | 0.0201 |
Biliary complications | 34 (16.9%) | 127 (16.7%) | 169 (21.7%) | 138 (22.3%) | 0.0151 |
Mean LOS in days (SD) | 44 (34) | 40 (30) | 41 (35) | 51 (43) | <0.0012 |